Overview
Location
United Kingdom, England, Bristol
Employees
1-10
Mentions in press and media 16
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Sep 11, 2026 | MammaTyper® LRP Score Demonstrates Prognostic Value in Early Luminal Breast Cancer | Study published in Clinical Breast Cancer supports MammaTyper® LRP as a quantitative molecular tool for risk assessment and chemotherapy decision-making MammaTyper® has the potential to become a broadly accessible multigene expression profi... |
| Jul 21, 2026 | Shuwen Biotech Announces South African Clinical Study of CercaTest RED™ for Short-Term Prediction of Preeclampsia | This study marks another important milestone in our mission to make innovative, rapid, accessible, and affordable preeclampsia risk assessment available to pregnant women worldwide.” — Jay Z. Zhang, Executive Chairman, Shuwen Biotech DEQING... |
| Apr 14, 2026 | Shuwen Biotech Receives Exclusive Patent License from Cologne University | DEQING, CHINA, April 14, 2026 /EINPresswire.com/ -- Shuwen Biotech, a leading biotech company, and its European Subsidiary Cerca Biotech GmbH today announced that they have signed an exclusive patent license agreement with the University Ho... |
| Nov 3, 2025 | Clinical Study Results on CercaTest RED™ Presented in 18th APCMFM | Our study suggests that CercaTest® RED could offer significant value in early detection in clinical settings and at home for early intervention, thereby improving maternal and fetal outcomes.” — Dr. Xiaoxia Bai, Zhejiang University Women's ... |
| Oct 27, 2025 | White Paper Published on HER2-Low Breast Cancer: the Case for Molecular Diagnostics | MammaTyper® provides a standardised, automated, reproducible test which is easy to implement in any lab that can improve patient selection for targeted therapies.” — Dr. Laia Bernet, Ribera Health Group, Spain BERLIN, GERMANY, October 27, 2... |
| Mar 14, 2025 | Seven MammaTyper® Studies Published in SGBCC | Studies add further evidence of clinical utilities of MammaTyper® in breast cancer subtyping and precision medicine The studies presented adds further evidence and support for the superior performance and clinical benefits of the MammaTyper... |
| Jan 13, 2025 | MammaTyper® Included in Leading Breast Cancer Guideline | Cerca Biotech’s innovative breast cancer molecular subtyping assay is recognized by leading professional associations in China BERLIN, GERMANY, January 13, 2025 /EINPresswire.com/ -- Cerca Biotech GmbH (“Cerca Biotech”) and Shuwen Biotech (... |
| Jul 30, 2024 | Shuwen Biotech Announces NMPA Approval for Pre-eclampsia Point of Care Test | CercaTest RED Pre-eclampsia Test Approved for both Professional Use and Self-testing at Home As onset and aggravation of pre-eclampsia may be sudden and unpredictable, continuous and remote testing could save lives especially in those at hi... |
| Mar 25, 2024 | Five MammaTyper® Studies Published in EBCC-14 | Studies demonstrate superior performance and clinical benefits of MammaTyper® in HER2 testing These studies demonstrate the superior performance and clinical benefits of our MammaTyper® assay, as compared to the traditional IHC approach, es... |
Show more
Reviews 0
FAQ about Cerca Biotech
What has the press written about Cerca Biotech?
Parsers VC has collected 16 articles mentioning Cerca Biotech, among them “MammaTyper® LRP Score Demonstrates Prognostic Value in Early Luminal Breast Cancer” (Sep 11, 2026) and “Shuwen Biotech Announces South African Clinical Study of CercaTest RED™ for Short-Term Prediction of Preeclampsia” (Jul 21, 2026).
Is Cerca Biotech still active?
Yes, Cerca Biotech is active; its latest activity on Parsers VC dates from Sep 17, 2026.